Synairgen Share Price | |
---|---|
Price | 5.76 |
Bid | 5.02 |
Ask | 6.50 |
Change | -0.15 (-2.54%) |
Volume | 91,513 |
Open | 5.91 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 5.91 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 201.37m |
Market Capitalisation | £11.90m |
Market Size | 30,000 |
52 Week High | 10.62 |
52 Week High Date | 29-Nov-2023 |
52 Week Low | 4.20 |
52 Week Low Date | 22-Mar-2024 |
# Trades | 9 |
---|---|
Vol. Sold | 84,157 |
Sold Value | £4.74k |
Vol. Bought | 7,356 |
Bought Value | £N/A |
PE Ratio | -0.674658 |
Earnings | -8.76 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
08-May-24 | 14:04:20 | 5.61 | 2,569 | Sell* | 5.02 | 6.50 | 144.12 | O Ordinary |
08-May-24 | 13:42:10 | 5.61 | 1,001 | Sell* | 5.02 | 6.50 | 56.16 | O Ordinary |
08-May-24 | 12:09:30 | 5.612 | 23,354 | Sell* | 5.02 | 6.50 | 1,311 | O Ordinary |
08-May-24 | 12:03:53 | 6.224 | 401 | Buy* | 5.02 | 6.50 | 24.96 | O Ordinary |
08-May-24 | 12:03:15 | 5.65 | 40,000 | Sell* | 5.02 | 6.50 | 2,260 | O Ordinary |
08-May-24 | 11:10:34 | 5.612 | 17,205 | Sell* | 5.02 | 6.50 | 965.54 | O Ordinary |
08-May-24 | 09:09:55 | 6.39 | 555 | Buy* | 5.02 | 6.50 | 35.46 | O Ordinary |
08-May-24 | 09:01:24 | 5.39 | 28 | Sell* | 5.02 | 6.50 | 1.51 | O Ordinary |
08-May-24 | 08:10:31 | 6.25 | 6,400 | Buy* | 5.02 | 6.50 | 400.00 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.74 | GBX | 7,899 | 8,520 |
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.42 | GBX | 621 | 8,520 |
12-Aug-21 | 12-Aug-21 | Sell | John C Ward held the position of Finance Director at the time of this trade.John C Ward | 140.00 | GBX | 269,963 | 734,092 |
12-Aug-21 | 12-Aug-21 | Exercise of Option | John C Ward held the position of Finance Director at the time of this trade.John C Ward | 1.00 | GBX | 489,148 | 734,092 |
12-Aug-21 | 12-Aug-21 | Sell | Phillip David Monk held the position of Chief Scientific Officer at the time of this trade.Phillip David Monk | 140.00 | GBX | 220,878 | 423,934 |
Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.